Literature DB >> 23044937

New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010?

Joel Lexchin.   

Abstract

Mesh：

Year:  2012        PMID： 23044937     DOI： 10.1001/archinternmed.2012.4444

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  28 in total

1.  Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.

Authors:  Joel Lexchin
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

2.  Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.

Authors:  Joel Lexchin; Tareq Ahmed
Journal:  CMAJ Open       Date:  2015-07-17

3.  Health Canada and the pharmaceutical industry: a preliminary analysis of the historical relationship.

Authors:  Joel Lexchin
Journal:  Healthc Policy       Date:  2013-11

4.  Post-approval safety issues with innovative drugs: a European cohort study.

Authors:  Peter G M Mol; Arna H Arnardottir; Domenico Motola; Patrick J Vrijlandt; Ruben G Duijnhoven; Flora M Haaijer-Ruskamp; Pieter A de Graeff; Petra Denig; Sabine M J M Straus
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

5.  Medicines Save, Medicines Kill.

Authors:  Joel Lexchin
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

6.  Cost recovery by Health Canada and drug safety: a time-series analysis.

Authors:  Joel Lexchin
Journal:  CMAJ Open       Date:  2018-10-18

7.  Grapefruit-medication interactions.

Authors:  David G Bailey
Journal:  CMAJ       Date:  2013-04-02       Impact factor: 8.262

8.  Priority reviews: innovation and safety.

Authors:  Joel Lexchin
Journal:  CMAJ       Date:  2017-07-04       Impact factor: 8.262

Review 9.  Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Authors:  Wolfgang Brück; Raff Gold; Brett T Lund; Celia Oreja-Guevara; Alexandre Prat; Collin M Spencer; Lawrence Steinman; Mar Tintoré; Timothy L Vollmer; Martin S Weber; Leslie P Weiner; Tjalf Ziemssen; Scott S Zamvil
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

10.  Why are there deadly drugs?

Authors:  Joel Lexchin
Journal:  BMC Med       Date:  2015-02-05       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.